EE Moore EE Moore Denver Health / University of Colorado Denver Denver Health / University of Colorado Denver Disclosure : Haemonetics & TEM Research Support.

Slides:



Advertisements
Similar presentations
Coagulopathy and blood component transfusion in trauma
Advertisements

The Basics of Hemophilia
Inflammation, Thrombosis, and Bleeding
Dr G Ogweno Consultant Anaesthesiologist and Lecturer in Medical Physiology Department of Medical Physiology Kenyatta University Nairobi, Kenya.
Uncontrolled Hemorrhagic Trauma: When all else fail to stop Mohamed Saleh, MD Department of Anesthesia and Intensive Care, Ain-Shams University.
Brad Beckham T4. Definitions  Major blood loss Hemoglobin concentration below 6-10 g/dl  Massive transfusion in adults >9 erythrocyte units within 24h.
Coagulation, Fluid, and Blood Management for Cardiac Surgery Maureane Hoffman, MD, PhD Professor of Pathology, Duke University and Director, Transfusion.
TXA in trauma patients: who should we treat and when?
ABC Advanced Bleeding Care Human Coagulation FVII Karsten Lollike.
An Overview of Hemostasis
Prehospital Air Medical Plasma (PAMPer) Trial TACTIC at AAST September 9th.
 An acquired syndrome characterized by systemic intravascular coagulation  Coagulation is always the initial event.  Most morbidity and mortality depends.
Haemostasis and NovoSeven®
Coagulation (the basics) and recombinant Factor VIIa Mechanism of Action Jerrold H. Levy, MD Emory University School of Medicine and Emory Healthcare Atlanta,
BLOOD BANKING 1- BLOOD PRODUCTS 2- AUTOLOGOUS TRANSFUSION M. H. Shaheen Maadi Armed Forces Hospital.
Management of the Bleeding Patient
Cristy M. Thomas FNP-BC University of Nevada School of Medicine University Medical Center, Las Vegas NV Nevada’s Only Level 1 Adult Trauma, Level 2 Pediatric.
Pathology of Coagulation I- Deficiency of Coagulation Factors II- II- HYPERCOAGULABLE STATES.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
TACTIC PROJECT 2: THE ROLE OF FACTOR XI IN TIC LEAD INVESTIGATOR: SAULIUS BUTENAS (UNIVERSITY OF VERMONT) CO-INVESTIGATOR: JAMES H MORRISSEY (UNIVERSITY.
Hemostasis/Thrombosis I Normal Hemostasis/Thrombosis; Assessment of Clotting System.
Anticoagulation In Dental Procedures Galila Zaher MRCPath KAU Assistant Professor.
Blood coagulation involves a biological amplification system in which relatively few initiation substances sequentially activate by proteolysis a cascade.
Normal Hemostasis Galila Zaher Consultant Hematologist KAUH.
Drmsaiem FIBRINOLSIS SYSTEM DR MOHAMMED SAIEMALDAHR Faculty of Applied Medical Sciences Medical Technology Dep.
Blood coagulation and fibrinolysis Professor Asim K. Duttaroy University of Oslo.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Implant of a Medical Device and the Wound Healing Process.
Scheme of Coagulation F XIIF XIIa F XIF XIa F IX F X F IXa F VIIaF VII Extrinsic System Tissue damage Release of tissue thromboplastine (F III) Intrinsic.
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
Clinical Utility of Thromboelastography (TEG)
DIC disseminated intravascular coagulation DIC is characterized by widespread coagulation and bleeding in the vascular compartment. DIC begins with massive.
Coagulation Mechanisms
Lt Col T Woolley FRCA RAMC Surg Lt Cdr Catherine Doran MRCS PGCAES RN Surg Capt M Midwinter DipAppStats MD FRCS RN NATO Medical Conference Royal Centre.
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Fibrinolysis and Hyperfibrinolysis TEG Analysis
The Biology of Bleeding and Clotting to Death Jeffrey H. Lawson, MD, PhD Director, Vascular Surgery Research Lab Director of Clinical Trials in Vascular.
PHYSIOLOGIC CONTROL OF HEMOSTASIS MLAB Coagulation Keri Brophy-Martinez.
MLAB Coagulation Keri Brophy-Martinez Fibrinolytic System.
Coagulation and fibrinolysis
Hemodynamics 2.
Plasma and plasma components in the management of disseminated intravascular coagulation Marcel Levi* Academic Medical Center, University of Amsterdam,
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
From: Treatment of Excessive Bleeding in Jehovah's Witness Patients after Cardiac Surgery with Recombinant Factor VIIa (NovoSeven®) Anesthes. 2003;98(6):
Platelets (Thrombocytes)
Revised model of coagulation
HAEMOSTASIS AND THROMBOSIS Regulation of coagulation
These factors prevent blood clotting - in normal state.
Activation of the Hemostatic System During Cardiopulmonary Bypass
Activation of the Hemostatic System During Cardiopulmonary Bypass
FIBRINOLSIS SYSTEM Ahmad Shihada Silmi Msc, FIBMS IUG
General Principles of Hemostasis Kristine Krafts, M.D.
What is haemostasis? Coagulation Fibrinolysis
Constituents of the blood: Platelets and plasma
Hemodynamic disorders (1 of 3)
and anti-thrombotic pharmocology Tom Williams
Coagulation and Anti-coagulation
Coagulation Cascade of the Newborn
Implant of a Medical Device and the Wound Healing Process.
Perioperative management of the bleeding patient
Review of haemostasis EACTS/ Hannes Meyer symposium 2012 Dr J Jordaan
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
How I treat patients with massive hemorrhage
George J. Despotis, MD, Michael S. Avidan, MD, Charles W. Hogue, MD 
Thromboelastography in Trauma
General Principles of Hemostasis Kristine Krafts, M.D.
Thrombosis and Inflammatory Bowel Disease
Antifibrinolytic therapy: new data and new concepts
Hemostasis Hemostasis depends on the integrity of Blood vessels
Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured.
Presentation transcript:

EE Moore EE Moore Denver Health / University of Colorado Denver Denver Health / University of Colorado Denver Disclosure : Haemonetics & TEM Research Support Disclosure : Haemonetics & TEM Research Support EE Moore EE Moore Denver Health / University of Colorado Denver Denver Health / University of Colorado Denver Disclosure : Haemonetics & TEM Research Support Disclosure : Haemonetics & TEM Research Support

20,211 Adult : SBP 110 within 8 Hr Mortality : 14.5% vs 16.0% ( p <.04) Death due to Bleeding : 4.9% vs 5.7% ( p <.08 ) Blood Transfusion … Only 50% of Patients No Reduction in Transfusion ( ~ 6 Units RBC ) CRASH-2 Trial : RCT / 274 Hospitals / 40 Countries Lancet 2010

Relative Risk < 1 hr = hr = 0.70 > 3 hr = 1.44 CRASH-2 Trial : RCT / 274 Hospitals / 40 Countries Lancet 2011

TIC : Factor Depletion vs Fibrinolysis TIC : Factor Depletion vs Fibrinolysis PC 1 PC 2 PC 3 Eigenvalue % Variance59% 14% 12% ACT74* K80*5 18 angle-96* MA-92*-35 3 LY *-3 TMRTG * MRTG-81* TTG-90*-37 3 Surgery2014

Shock Enhances Fibrinolysis … Tissue Injury Inhibits Fibrinolysis

Trauma Study Population 193 patients 70% male, Age 44 Median ISS 29 ( IQR ) Median BD 9 ( IQR 6-13 ) 21% Mortality21% Mortality

Postinjury Spectrum of Fibrinolysis Microvascular Occlusion Vascular Patency Uncontrolled Bleeding N=37 ( 19% ) N=37 ( 19% ) N=156 ( 71% ) N=156 ( 71% ) N=33 ( 17% ) N=33 ( 17% ) N=123 ( 64% ) N=123 ( 64% ) Mortality = 19 ( 58% ) Mortality = 19 ( 58% ) Mortality = 20 ( 16% ) Mortality = 20 ( 16% ) Mortality = 1 ( 3% ) Mortality = 1 ( 3% )

Clinical Outcomes : Fibrinolysis J Trauma 2014

Fibrinolysis Phenoype : Mortality Fibrinolysis Phenoype : Mortality

Hyperfibrinolysis = PAI-1 Depletion

Fibrinolysis Shutdown = Excessive PAI-1

TPATPA ? tPA Complexed Non PAI- 1 Inhibitio n ? tPA Augmentation ? ? TPA Challenge % LY30 TPA Levels

Platelet Fibrin Polymer Plasminogen and sc-tPA Converted Plasmin and tc-tPA Granule (Alpha, Dense) Granule (Alpha, Dense) Sc-tPA PAI-1 ? ? TAFI Alpha 2 Anti-plasmin Cross linking (factor XIII) Fibrinolysis Fibrin Degradation Products Alpha 2 Macroglobulin Direct tPA Inhibition Direct Plasmin Inhibition Fibrinogen

Potential Mechanisms For Phenotypes Red Blood Cell Degradation in Major TraumaRed Blood Cell Degradation in Major Trauma Proteomics: Shock Wohlauer et al 2010 Metabolomics: J Metabolomics D’alessandro In press Platelet Transfusion Associated with MOFPlatelet Transfusion Associated with MOF –Granules contain anti-fibrinolytics

Study Methods Citrated Volunteers Whole Blood –% replaced with Lysed Own RBCs Donor Platelets Leukoreduced RBCS tPA TEG ChallengetPA TEG Challenge –Exogenous tPA mixed with blood –Run on TEG –75ng/ml final concentration –Ly30: Lysis at 30 min used for assessment of fibrinolysis

Lysed RBCs Enhance tPA Mediated Fibrinolysis at a Low Dose

Lysed Platelets Shutdown Fibrinolysis at a Low Dose

Credits : UCD Trauma Research Team Mike Chapman Theresa Chin Eduardo Gonzalez Hunter Moore Max Wohlauer Ani Banerjee Kirk Hansen Angela Sauaia Chris Silliman NIH P50 GM 4922 NIH T32 GM NIH UM1 HL Sarah Ammons Jim Chandler Andrea Emard Cortney Fleming Arsen Ghasabyan Ray Shepard-Singh Carl Barnett Denis Bensrad Walt Biffl Clay Burlew Chuck Fox Jerry Jurkovich Fred Pieracci Rob Stoval

Thank you !!! TF-Bearing Cell Activated Platelet Platelet TF VIIIa Va VIIIa Va Va VIIa TF VIIa X Xa IIa IX VVa II VIII / vWF VIIIa II IXa X IX X IXa IXa VIIa Xa IIa IIa Xa

Hyperfibrinolysis : Early Mortality Shutdown : Delayed Mortality Hyperfibrinolysis Shutdown

Postinjury Hyperfibrinolysis Postinjury Hyperfibrinolysis Genetics Co –Morbidity Medication Hypoxia Tissue Injury Adrenaline HistonesElastaseHMGB1ComplementHistonesElastaseHMGB1Complement Endothelial Dysfunction Activated Protein C tPA Plasmin PAI-1 Fibrinolysi S TRAUMA INDUCED COAGULOPATHY TRAUMA INDUCED COAGULOPATHY AcidosisAcidosis HypothermiaHypothermia DilutionDilution ConsumptionConsumption ? Tissue Factor Thrombin FXIIIa sThrombomodulin Heparan Sulfate sCD40L

TIC : Principal Component Analysis TIC : Principal Component Analysis Kutcher, Cohen et al J Trauma 2013

Blood Component Transfusion

Incidence of Postinjury Fibrinolysis Denver = 2% Activations ( 17 % M Transfusion )Denver = 2% Activations ( 17 % M Transfusion ) Houston = 2% ActivationsHouston = 2% Activations Lyon = 6% ActivationsLyon = 6% Activations Salzburg = 8% ActivationsSalzburg = 8% Activations Los Angeles = ( 10% M Transfusion )Los Angeles = ( 10% M Transfusion ) San Francisco = ( 20% M Transfusion )San Francisco = ( 20% M Transfusion )

Recent Trauma Experience in the US J Trauma 2014